AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / Management Team / Ashley J. Meyers appointed President and COO of AntoXa Corporation

Ashley J. Meyers appointed President and COO of AntoXa Corporation

December 20, 2018

Guelph, Ont., Canada, Dec. 20, 2018 — AntoXa Corporation announced today that Ms. Ashley J. Meyers has been appointed President and Chief Operating Officer (COO).

Ashley J. Meyers, President and COO of AntoXa Corporation.

Ms. Meyers has been a member of the Canadian biopharmaceutical company’s leadership team since the company’s inception. She brings more than 10 years of experience in drug research and development with a focus on recombinant proteins and production of these products for pre-clinical trials.

“We’re very pleased that Ashley will be taking the reins to lead AntoXa through the company’s next stage of growth and development,” said Dr. Don Stewart, AntoXa’s CEO and founding president. “She has been leading our medical countermeasures research and development programs since 2012 and has secured more than $2.2 million towards advancing these programs.”

Ms. Meyers will continue work to develop three key assets:

  • PhD9 anti-ricin antibody
  • BuChE, a countermeasure for sarin and soman nerve agents
  • biosimilar Herceptin to treat trauma in military personnel and civilians

In April, AntoXa was granted a license from Defence Research & Development Canada (DRDC), an agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale in markets worldwide.

“Ashley’s leadership and expertise will be an important asset as AntoXa continues to build partnerships with investors and government agencies to bring these important drugs to market,” Stewart said.

Ms. Meyers completed a M.Sc. degree in protein engineering in plants from the University of Guelph under the supervision of Dr. J.Christopher Hall, PlantForm’s co-founder and Chief Scientific Officer and a member of the AntoXa Board of Directors. In addition to her work with AntoXa, she has over five years of experience as a project manager for government-funded contracts for PlantForm Corporation and is a certified Project Management Professional (PMP).

About AntoXa Corporation (www.antoxacorp.com)

AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents, as well as outbreaks of naturally occurring infectious diseases.

A wholly-owned subsidiary of PlantForm Corporation, AntoXa holds an exclusive licence to the vivoXPRESS® biopharmaceutical manufacturing platform to produce countermeasures for ricin, sarin, soman and Ebola Sudan, as well as other defence-related therapeutics.

vivoXPRESS® technology uses genetically engineered tobacco plants to produce biopharmaceuticals in less than six weeks at a significantly lower cost of goods compared to industry standard fermentation systems.

– end –

For more information, please contact:

Ashley J. Meyers
President and COO, AntoXa Corp.
[email protected]
+905-852-0850

Stacey Curry Gunn
Director of Communications, AntoXa Corp.
[email protected]
+1 519-827-1131

Filed Under: Management Team, News Releases

Latest News

AntoXa and SwiftPharma to present plant-made anti-ricin antibody technology to NATO expert panel

August 14, 2024

GUELPH, Ont., Canada, August 14, 2024 — AntoXa Corporation, a Canadian ...
Read more >

New Patent for AntoXa’s Plant-Made Anti-Ricin Antibody Manufacturing Process

January 30, 2024

GUELPH, Ont., Canada, January 30, 2024 — The Canadian Intellectual ...
Read more >

AntoXa Corporation and SwiftPharma Sign Exclusive Collaboration Agreement to Support the Development and Commercialization of a Plant-Made Antibody Against Ricin Exposure

September 5, 2023

GHENT, Belgium and TORONTO, Canada, September 5, 2023 – AntoXa ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2025 · AntoXa Corporation | Site by Curry Gunn & Associates